Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04795479 · ClinicalTrials.gov registry record · Phase 1
T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers
A Phase 1 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT04795479 is a Phase 1 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 36 participants.
The verdict
NCT04795479, a Phase 1 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This dedicated T/QT study will investigate the effect of relacorilant on cardiac repolarization in healthy participants.
Interventions
- DRUG Moxifloxacin
- DRUG Relacorilant
- DRUG Placebo to relacorilant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-01-22 |
| Est. Completion | 2021-07-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04795479
The ClinicalTrials.gov registry entry for NCT04795479 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Moxifloxacin is the first listed.
NCT04795479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04795479 about?
NCT04795479 is a clinical study titled "T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers". This dedicated T/QT study will investigate the effect of relacorilant on cardiac repolarization in healthy participants.
What is the current status of trial NCT04795479?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-01-22. Estimated completion is 2021-07-13.
What interventions are being tested in trial NCT04795479?
The interventions under investigation include: Moxifloxacin (DRUG), Relacorilant (DRUG), Placebo to relacorilant (DRUG).
Who is sponsoring clinical trial NCT04795479?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.